Lung cancer is the leading cause of cancer mortality worldwide. Recent progress has improved outcomes for many lung cancer patients. In particular, activating genetic alterations in the oncogenic driver genes such as the epidermal growth factor receptor (EGFR) are now successfully targeted with agents such as the EGFR tyrosine kinase inhibitor osimertinib. Despite progress, drug resistance remains a barrier to complete and long-term tumor responses. Indeed, most patients do not survive with EGFR mutant lung cancer as a chronic disease and instead succumb to the disease within a few years due to the emergence of resistance.
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
The series “Mechanisms of Resistance to EGFR-targeted Therapy” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Trever G. Bivona served as the unpaid Guest Editor for the series.